Spots Global Cancer Trial Database for immunoenzyme technique
Every month we try and update this database with for immunoenzyme technique cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate | NCT00459407 | Adenocarcinoma ... Stage I Prostat... Stage II Prosta... | defined green t... placebo immunohistochem... immunoenzyme te... laboratory biom... biopsy mass spectromet... high performanc... | 18 Years - | National Cancer Institute (NCI) | |
| Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy | NCT00897520 | Melanoma (Skin) | recombinant int... proteomic profi... immunoenzyme te... laboratory biom... | - 120 Years | Eastern Cooperative Oncology Group | |
| ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00770471 | Brain and Centr... | temozolomide veliparib DNA methylation... gene expression... mutation analys... proteomic profi... high performanc... immunoenzyme te... laboratory biom... mass spectromet... pharmacogenomic... pharmacological... adjuvant therap... radiation thera... | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer | NCT01058785 | Lung Neoplasm Carcinoma, Bron... | Lucanix | 18 Years - | NovaRx Corporation | |
| Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment | NCT00673569 | Lung Cancer | erlotinib hydro... gene expression... protein express... immunoenzyme te... immunologic tec... laboratory biom... needle biopsy | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors | NCT00372736 | Unspecified Adu... | AEG35156 docetaxel protein express... reverse transcr... flow cytometry immunoenzyme te... immunohistochem... laboratory biom... | 18 Years - | Canadian Cancer Trials Group | |
| Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission | NCT00522301 | Fallopian Tube ... Ovarian Cancer Primary Periton... | sorafenib tosyl... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission | NCT00522301 | Fallopian Tube ... Ovarian Cancer Primary Periton... | sorafenib tosyl... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma | NCT00398138 | Leukemia Lung Cancer Malignant Mesot... Myelodysplastic... Primary Periton... | WT-1 analog pep... incomplete Freu... sargramostim polymerase chai... flow cytometry immunoenzyme te... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer | NCT00492440 | Kidney Cancer Melanoma (Skin) | recombinant int... gene expression... polymerase chai... protein express... flow cytometry immunoenzyme te... immunologic tec... laboratory biom... pharmacological... | 18 Years - | Cytheris SA | |
| Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide | NCT00899080 | Multiple Myelom... | gene expression... reverse transcr... immunoenzyme te... laboratory biom... platelet aggreg... | - 120 Years | Eastern Cooperative Oncology Group | |
| Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection | NCT00513461 | Adult Primary L... Hepatitis C Inf... | S-adenosyl-L-me... placebo laboratory biom... immunoenzyme te... high performanc... | 18 Years - | University of California, Irvine | |
| Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma | NCT00512798 | Brain and Centr... Melanoma Solid Tumor | PS-341 (VELCADE... temozolomide immunoenzyme te... PS-341 (VELCADE... Temozolomide | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| A Weight-Loss Program in Helping Obese Black Women Lose Weight | NCT00859989 | Breast Cancer Obesity Weight Changes | behavioral diet... exercise interv... telephone-based... counseling inte... educational int... immunoenzyme te... laboratory biom... questionnaire a... study of socioe... evaluation of c... support group t... | 30 Years - 50 Years | National Cancer Institute (NCI) | |
| Diet and Exercise or Normal Care in Overweight or Obese Women Who Have Undergone Treatment for Stage I, Stage II, or Stage III Breast Cancer | NCT00689975 | Breast Cancer | behavioral diet... exercise interv... counseling inte... flow cytometry immunoenzyme te... laboratory biom... complementary o... standard follow... | - | National Cancer Institute (NCI) | |
| A Weight-Loss Program in Helping Obese Black Women Lose Weight | NCT00859989 | Breast Cancer Obesity Weight Changes | behavioral diet... exercise interv... telephone-based... counseling inte... educational int... immunoenzyme te... laboratory biom... questionnaire a... study of socioe... evaluation of c... support group t... | 30 Years - 50 Years | National Cancer Institute (NCI) | |
| Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma | NCT00822848 | Sarcoma | epirubicin hydr... ifosfamide sorafenib tosyl... immunoenzyme te... immunohistochem... laboratory biom... adjuvant therap... neoadjuvant the... therapeutic con... hypofractionate... | 15 Years - 120 Years | OHSU Knight Cancer Institute | |
| Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma | NCT00398138 | Leukemia Lung Cancer Malignant Mesot... Myelodysplastic... Primary Periton... | WT-1 analog pep... incomplete Freu... sargramostim polymerase chai... flow cytometry immunoenzyme te... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery | NCT00096590 | Thromboembolism Unspecified Adu... | coagulation stu... immunoenzyme te... laboratory biom... physiologic tes... study of high r... | 18 Years - | National Cancer Institute (NCI) | |
| Study of Cerebrospinal Fluid Samples in Diagnosing Carcinomatous Meningitis in Patients With Cancer or Meningeal Syndrome | NCT00938756 | Brain and Centr... Breast Cancer Metastatic Canc... | diagnostic labo... immunoenzyme te... magnetic resona... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma | NCT01239875 | Cutaneous B-cel... Extranodal Marg... Nodal Marginal ... Adult Diffuse M... Adult Diffuse S... Adult Grade III... Adult Immunobla... Adult Lymphobla... Grade 1 Follicu... Grade 2 Follicu... Grade 3 Follicu... Mantle Cell Lym... Marginal Zone L... Small Lymphocyt... Splenic Margina... Waldenstrom Mac... | dendritic cell ... cryotherapy pneumococcal po... laboratory biom... immunoenzyme te... immunohistochem... autologous dend... | 18 Years - 90 Years | Mayo Clinic | |
| Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer | NCT00897702 | Breast Cancer | Blood draw immunoenzyme te... biopsy histopathologic... | - | Memorial Sloan Kettering Cancer Center | |
| Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer | NCT00492440 | Kidney Cancer Melanoma (Skin) | recombinant int... gene expression... polymerase chai... protein express... flow cytometry immunoenzyme te... immunologic tec... laboratory biom... pharmacological... | 18 Years - | Cytheris SA | |
| Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors | NCT00388089 | Lung Cancer Unspecified Adu... | bortezomib topotecan hydro... flow cytometry immunoenzyme te... immunohistochem... laboratory biom... | 18 Years - | University of California, Davis | |
| Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma | NCT01239875 | Cutaneous B-cel... Extranodal Marg... Nodal Marginal ... Adult Diffuse M... Adult Diffuse S... Adult Grade III... Adult Immunobla... Adult Lymphobla... Grade 1 Follicu... Grade 2 Follicu... Grade 3 Follicu... Mantle Cell Lym... Marginal Zone L... Small Lymphocyt... Splenic Margina... Waldenstrom Mac... | dendritic cell ... cryotherapy pneumococcal po... laboratory biom... immunoenzyme te... immunohistochem... autologous dend... | 18 Years - 90 Years | Mayo Clinic | |
| Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107 | NCT00898547 | Malignant Mesot... | immunoenzyme te... laboratory biom... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma | NCT00512798 | Brain and Centr... Melanoma Solid Tumor | PS-341 (VELCADE... temozolomide immunoenzyme te... PS-341 (VELCADE... Temozolomide | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck | NCT00720304 | Head and Neck C... | docetaxel erlotinib hydro... fluorescence in... polymerase chai... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... therapeutic con... intensity-modul... radiation thera... | 18 Years - | Case Comprehensive Cancer Center | |
| Study of Proteins in Head and Neck Cancer Cells | NCT00896948 | Head and Neck C... | Southern blotti... TdT-mediated dU... gene expression... protein express... flow cytometry fluorescent ant... immunoenzyme te... immunohistochem... immunologic tec... | - 120 Years | Vanderbilt University Medical Center | |
| Dasatinib in Treating Patients With Stage IV Pancreatic Cancer | NCT00544908 | Pancreatic Canc... | dasatinib immunoenzyme te... immunohistochem... laboratory biom... quality-of-life... | 18 Years - | City of Hope Medical Center | |
| Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission | NCT00522301 | Fallopian Tube ... Ovarian Cancer Primary Periton... | sorafenib tosyl... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors | NCT00714181 | Unspecified Adu... | hydroxychloroqu... temozolomide TdT-mediated dU... western blottin... electron micros... high performanc... immunoenzyme te... immunohistochem... laboratory biom... mass spectromet... pharmacological... | 18 Years - 120 Years | Abramson Cancer Center at Penn Medicine | |
| PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer | NCT00589550 | Kidney Cancer | PEG-interferon ... Sorafenib gene expression... polymerase chai... reverse transcr... flow cytometry immunoenzyme te... laboratory biom... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma | NCT00897910 | Multiple Myelom... | flow cytometry immunoenzyme te... laboratory biom... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma | NCT00233948 | Adult Liposarco... Recurrent Adult... Stage III Adult... Stage IV Adult ... | nelfinavir mesy... biopsy laboratory biom... pharmacological... gene expression... western blottin... reverse transcr... immunoenzyme te... | 18 Years - | City of Hope Medical Center | |
| Study of Blood Samples From Older Patients at High Risk of Developing Prostate Cancer and From Healthy Male Participants | NCT00898274 | Precancerous Co... Prostate Cancer | immunoenzyme te... laboratory biom... | 45 Years - 65 Years | Case Comprehensive Cancer Center | |
| Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer | NCT00896857 | Breast Cancer | RNA analysis polymerase chai... protein express... reverse transcr... western blottin... immunoenzyme te... immunohistochem... laboratory biom... breast duct lav... | - 120 Years | Wake Forest University Health Sciences | |
| Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors | NCT00714181 | Unspecified Adu... | hydroxychloroqu... temozolomide TdT-mediated dU... western blottin... electron micros... high performanc... immunoenzyme te... immunohistochem... laboratory biom... mass spectromet... pharmacological... | 18 Years - 120 Years | Abramson Cancer Center at Penn Medicine | |
| Early Detection of Second Lung Cancer in Patients With Stage I Non-small Cell Lung Cancer | NCT00002667 | Lung Cancer | cytology specim... immunoenzyme te... study of high r... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Biomarkers in Samples From Patients With Chronic Lymphocytic Leukemia Treated on Clinical Trial ECOG-2997 | NCT00899873 | Leukemia | cytogenetic ana... flow cytometry fluorescence ac... immunoenzyme te... laboratory biom... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors | NCT00389805 | Lung Cancer Unspecified Adu... | bortezomib pemetrexed diso... gene expression... mutation analys... protein express... reverse transcr... flow cytometry immunoenzyme te... immunohistochem... | 18 Years - 120 Years | University of California, Davis | |
| Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer | NCT00362882 | Non-small Cell ... Recurrent Non-s... Stage IV Non-sm... | docetaxel bortezomib laboratory biom... immunoenzyme te... immunohistochem... pharmacological... | 18 Years - 120 Years | National Cancer Institute (NCI) | |
| Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer | NCT00514215 | Kidney Cancer Lung Cancer Metastatic Canc... Unspecified Adu... | sargramostim flow cytometry immunoenzyme te... biopsy cryosurgery | 18 Years - 120 Years | Barbara Ann Karmanos Cancer Institute | |
| Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment | NCT00673569 | Lung Cancer | erlotinib hydro... gene expression... protein express... immunoenzyme te... immunologic tec... laboratory biom... needle biopsy | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma | NCT01239875 | Cutaneous B-cel... Extranodal Marg... Nodal Marginal ... Adult Diffuse M... Adult Diffuse S... Adult Grade III... Adult Immunobla... Adult Lymphobla... Grade 1 Follicu... Grade 2 Follicu... Grade 3 Follicu... Mantle Cell Lym... Marginal Zone L... Small Lymphocyt... Splenic Margina... Waldenstrom Mac... | dendritic cell ... cryotherapy pneumococcal po... laboratory biom... immunoenzyme te... immunohistochem... autologous dend... | 18 Years - 90 Years | Mayo Clinic | |
| PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer | NCT00589550 | Kidney Cancer | PEG-interferon ... Sorafenib gene expression... polymerase chai... reverse transcr... flow cytometry immunoenzyme te... laboratory biom... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Etoposide and Celecoxib in Patients With Advanced Cancer | NCT00551005 | Unspecified Adu... | celecoxib etoposide immunoenzyme te... laboratory biom... | 18 Years - | City of Hope Medical Center | |
| S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors | NCT00788580 | Unspecified Adu... | pazopanib hydro... temsirolimus immunoenzyme te... laboratory biom... pharmacological... | 18 Years - | SWOG Cancer Research Network | |
| Dasatinib in Treating Patients With Stage IV Pancreatic Cancer | NCT00544908 | Pancreatic Canc... | dasatinib immunoenzyme te... immunohistochem... laboratory biom... quality-of-life... | 18 Years - | City of Hope Medical Center | |
| Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine | NCT00228358 | HER2-positive B... Recurrent Breas... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Stage IV Breast... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... | ex vivo-expande... cyclophosphamid... denileukin dift... flow cytometry immunoenzyme te... | 18 Years - | University of Washington | |
| AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors | NCT00372736 | Unspecified Adu... | AEG35156 docetaxel protein express... reverse transcr... flow cytometry immunoenzyme te... immunohistochem... laboratory biom... | 18 Years - | Canadian Cancer Trials Group | |
| Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer | NCT00847171 | Breast Cancer | allogeneic GM-C... trastuzumab cyclophosphamid... flow cytometry immunoenzyme te... immunohistochem... laboratory biom... pharmacological... biopsy | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer | NCT00436254 | HER2-positive B... Stage III Ovari... Stage III Ovari... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Stage IV Ovaria... Stage IV Ovaria... | pNGVL3-hICD vac... sargramostim flow cytometry immunologic tec... immunoenzyme te... protein express... biopsy | 18 Years - | University of Washington | |
| Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery | NCT00471484 | Liver Cancer | recombinant int... doxorubicin hyd... fluorouracil oxaliplatin diagnostic labo... immunoenzyme te... immunohistochem... adjuvant therap... biopsy neoadjuvant the... therapeutic con... | 16 Years - 75 Years | National Cancer Institute (NCI) | |
| Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma | NCT00398138 | Leukemia Lung Cancer Malignant Mesot... Myelodysplastic... Primary Periton... | WT-1 analog pep... incomplete Freu... sargramostim polymerase chai... flow cytometry immunoenzyme te... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery | NCT00646659 | Head and Neck C... | cetuximab carboplatin cisplatin docetaxel fluorouracil fluorescence in... molecular genet... reverse transcr... immunoenzyme te... immunohistochem... laboratory biom... biopsy 3-dimensional c... intensity-modul... | 18 Years - 75 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer | NCT00436254 | HER2-positive B... Stage III Ovari... Stage III Ovari... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Stage IV Ovaria... Stage IV Ovaria... | pNGVL3-hICD vac... sargramostim flow cytometry immunologic tec... immunoenzyme te... protein express... biopsy | 18 Years - | University of Washington | |
| Exercise Programs in Healthy Young Women at Increased Risk of Developing Breast Cancer | NCT00892515 | Breast Cancer Healthy, no Evi... | exercise interv... counseling inte... gas chromatogra... immunoenzyme te... immunologic tec... laboratory biom... mass spectromet... physiologic tes... questionnaire a... survey administ... dual x-ray abso... magnetic resona... study of high r... | 18 Years - 35 Years | Abramson Cancer Center at Penn Medicine | |
| Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery | NCT01340599 | Stage I Prostat... Stage IIA Prost... Stage IIB Prost... | defined green t... placebo immunohistochem... immunoenzyme te... questionnaire a... therapeutic con... high performanc... mass spectromet... | 45 Years - 75 Years | Case Comprehensive Cancer Center | |
| Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma | NCT00498927 | Brain and Centr... | temozolomide protein express... reverse transcr... diagnostic labo... immunoenzyme te... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery | NCT00646659 | Head and Neck C... | cetuximab carboplatin cisplatin docetaxel fluorouracil fluorescence in... molecular genet... reverse transcr... immunoenzyme te... immunohistochem... laboratory biom... biopsy 3-dimensional c... intensity-modul... | 18 Years - 75 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women) | NCT00499083 | Breast Cancer | therapeutic aut... aromatase inhib... cyclophosphamid... doxorubicin hyd... paclitaxel tamoxifen citra... gene expression... protein express... reverse transcr... immunoenzyme te... immunohistochem... laboratory biom... adjuvant therap... biopsy conventional su... neoadjuvant the... radiation thera... | 19 Years - 120 Years | University of Nebraska | |
| Early Detection of Second Lung Cancer in Patients With Stage I Non-small Cell Lung Cancer | NCT00002667 | Lung Cancer | cytology specim... immunoenzyme te... study of high r... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck | NCT00720304 | Head and Neck C... | docetaxel erlotinib hydro... fluorescence in... polymerase chai... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... therapeutic con... intensity-modul... radiation thera... | 18 Years - | Case Comprehensive Cancer Center | |
| Exercise Programs in Healthy Young Women at Increased Risk of Developing Breast Cancer | NCT00892515 | Breast Cancer Healthy, no Evi... | exercise interv... counseling inte... gas chromatogra... immunoenzyme te... immunologic tec... laboratory biom... mass spectromet... physiologic tes... questionnaire a... survey administ... dual x-ray abso... magnetic resona... study of high r... | 18 Years - 35 Years | Abramson Cancer Center at Penn Medicine | |
| Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer | NCT00899197 | Breast Cancer | tamoxifen citra... gene expression... protein express... immunoenzyme te... laboratory biom... | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck | NCT00720304 | Head and Neck C... | docetaxel erlotinib hydro... fluorescence in... polymerase chai... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... therapeutic con... intensity-modul... radiation thera... | 18 Years - | Case Comprehensive Cancer Center | |
| Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing Surgery | NCT00671476 | Breast Cancer | pegylated lipos... DNA methylation... TdT-mediated dU... fluorescence in... loss of heteroz... polymerase chai... immunoenzyme te... immunohistochem... laboratory biom... breast duct lav... neoadjuvant the... therapeutic con... | 18 Years - | National Cancer Institute (NCI) | |
| Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery | NCT00410956 | Liver Cancer | bevacizumab dexamethasone floxuridine protein express... flow cytometry immunoenzyme te... immunohistochem... immunologic tec... laboratory biom... dynamic contras... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck | NCT00720304 | Head and Neck C... | docetaxel erlotinib hydro... fluorescence in... polymerase chai... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... therapeutic con... intensity-modul... radiation thera... | 18 Years - | Case Comprehensive Cancer Center | |
| Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery | NCT00096590 | Thromboembolism Unspecified Adu... | coagulation stu... immunoenzyme te... laboratory biom... physiologic tes... study of high r... | 18 Years - | National Cancer Institute (NCI) | |
| Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer | NCT00089609 | Prostatic Neopl... | Docetaxel Thalidomide Prednisone bevacizumab polymorphism an... immunoenzyme te... laboratory biom... pharmacological... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer | NCT00690872 | Head and Neck C... | autologous Epst... carboplatin gemcitabine hyd... polymerase chai... fluorescence ac... immunoenzyme te... | 21 Years - | National Cancer Institute (NCI) | |
| DNA Analysis of Tumor Tissue Samples From Patients With Human Papilloma Virus-Associated Cancer of the Oropharynx | NCT00897988 | Head and Neck C... | gene expression... mutation analys... polyacrylamide ... polymerase chai... protein express... reverse transcr... flow cytometry immunoenzyme te... immunologic tec... laboratory biom... pharmacological... | - 120 Years | Vanderbilt University Medical Center | |
| Studying Blood Samples in Women With Breast Cancer or a History of Breast Cancer | NCT00898703 | Breast Cancer | flow cytometry immunoenzyme te... laboratory biom... | - | University of Arizona | |
| Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer | NCT00470574 | Breast Cancer | QS21 sialyl Lewisª-k... immunoenzyme te... immunologic tec... laboratory biom... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | NCT00729612 | Lung Cancer | carboplatin paclitaxel albu... protein express... immunoenzyme te... immunohistochem... laboratory biom... | 18 Years - 120 Years | Ohio State University Comprehensive Cancer Center | |
| ABT-510 in Treating Patients With Metastatic Melanoma | NCT00602199 | Melanoma (Skin) | ABT-510 immunoenzyme te... immunohistochem... laboratory biom... pharmacological... biopsy | 18 Years - | Mayo Clinic | |
| Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer | NCT00436709 | Breast Cancer | bevacizumab pegfilgrastim cyclophosphamid... doxorubicin hyd... paclitaxel albu... flow cytometry immunoenzyme te... immunologic tec... laboratory biom... adjuvant therap... immunoscintigra... | 18 Years - | National Cancer Institute (NCI) | |
| ABT-510 in Treating Patients With Metastatic Melanoma | NCT00602199 | Melanoma (Skin) | ABT-510 immunoenzyme te... immunohistochem... laboratory biom... pharmacological... biopsy | 18 Years - | Mayo Clinic |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
